{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:26:11Z","timestamp":1785147971114,"version":"3.55.0"},"reference-count":277,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015919","name":"A Glimmer of Hope","doi-asserted-by":"publisher","award":["A Glimmer of Hope"],"award-info":[{"award-number":["A Glimmer of Hope"]}],"id":[{"id":"10.13039\/100015919","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peritoneal carcinomatosis (PC) is a complex manifestation of abdominal cancers, with a poor prognosis and limited treatment options. Recent work identifying high concentrations of the cytokine interleukin-6 (IL-6) and its soluble receptor (sIL-6-R\u03b1) in the peritoneal cavity of patients with PC has highlighted this pathway as an emerging potential therapeutic target. This review article provides a comprehensive overview of the current understanding of the potential role of IL-6 in the development and progression of PC. We discuss mechansims by which the IL-6 pathway may contribute to peritoneal tumor dissemination, mesothelial adhesion and invasion, stromal invasion and proliferation, and immune response modulation. Finally, we review the prospects for targeting the IL-6 pathway in the treatment of PC, focusing on common sites of origin, including ovarian, gastric, pancreatic, colorectal and appendiceal cancer, and mesothelioma.<\/jats:p>","DOI":"10.1186\/s12967-024-05205-8","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:01:50Z","timestamp":1714496510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis"],"prefix":"10.1186","volume":"22","author":[{"given":"Neda","family":"Dadgar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Donnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Donnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"5205_CR1","doi-asserted-by":"crossref","unstructured":"Tepel J, Ajah D. The natural course of peritoneal carcinomatosis (PC). Peritoneal tumors and metastases: Surgical, intraperitoneal and systemic therapy. Springer; 2021. pp. 55\u20138.","DOI":"10.1007\/978-3-030-62640-2_6"},{"issue":"11","key":"5205_CR2","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","volume":"19","author":"V Kepenekian","year":"2022","unstructured":"Kepenekian V, Bhatt A, P\u00e9ron J, Alyami M, Benzerdjeb N, Bakrin N, et al. Advances in the management of peritoneal malignancies. Nat Reviews Clin Oncol. 2022;19(11):698\u2013718.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"5205_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/10717544.2021.1937382","volume":"28","author":"SJ Park","year":"2021","unstructured":"Park SJ, Lee EJ, Lee HS, Kim J, Park S, Ham J, et al. Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum. Drug Delivery. 2021;28(1):1179\u201387.","journal-title":"Drug Delivery"},{"issue":"12","key":"5205_CR4","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1080\/17425247.2019.1693997","volume":"16","author":"PH Sugarbaker","year":"2019","unstructured":"Sugarbaker PH. Intraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: current challenges and how to overcome them. Expert Opin Drug Deliv. 2019;16(12):1393\u2013401.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"5205_CR5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/cancers14030570","volume":"14","author":"BJ Sun","year":"2022","unstructured":"Sun BJ, Lee B. Review of regional therapies for gastric cancer with peritoneal metastases. Cancers. 2022;14(3):570.","journal-title":"Cancers"},{"key":"5205_CR6","first-page":"515","volume-title":"Perfusion for hyperthermic intraperitoneal chemotherapy by cardiopulmonary bypass machine","author":"M Duman","year":"2023","unstructured":"Duman M, Polat E, Can M, K\u0131rali K, Ersoy E. Perfusion for hyperthermic intraperitoneal chemotherapy by cardiopulmonary bypass machine. Cardiopulmonary Bypass: Elsevier; 2023. pp. 515\u201326."},{"issue":"11","key":"5205_CR7","first-page":"4272","volume":"7","author":"Y-Q Ai","year":"2014","unstructured":"Ai Y-Q, Cai K, Hu J-H, Jiang L-W, Gao Y-R, Zhao H, et al. The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. Int J Clin Exp Med. 2014;7(11):4272.","journal-title":"Int J Clin Exp Med"},{"issue":"9","key":"5205_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Sch\u00fc\u00dfler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183\u201397.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"5205_CR9","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127(9):2209\u201321.","journal-title":"Int J Cancer"},{"issue":"18","key":"5205_CR10","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","volume":"24","author":"UM Lauer","year":"2018","unstructured":"Lauer UM, Schell M, Beil J, Berchtold S, Koppenh\u00f6fer U, Glatzle J, et al. Phase I study of Oncolytic Vaccinia Virus GL-ONC1 in patients with peritoneal CarcinomatosisGL-ONC1 virotherapy of Peritoneal Carcinomatosis. Clin Cancer Res. 2018;24(18):4388\u201398.","journal-title":"Clin Cancer Res"},{"key":"5205_CR11","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1245\/s10434-020-09464-9","volume":"28","author":"R Ramanathan","year":"2021","unstructured":"Ramanathan R, Choudry H, Jones H, Girgis M, Gooding W, Kalinski P, et al. Phase II trial of adjuvant dendritic cell vaccine in combination with celecoxib, interferon-\u03b1, and rintatolimod in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases. Ann Surg Oncol. 2021;28:4637\u201346.","journal-title":"Ann Surg Oncol"},{"key":"5205_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00262-009-0750-3","volume":"59","author":"AM Vlad","year":"2010","unstructured":"Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother. 2010;59:293\u2013301.","journal-title":"Cancer Immunol Immunother"},{"key":"5205_CR13","doi-asserted-by":"crossref","unstructured":"Wagner P, Donnenberg V, Pico CC, Donnenberg A, Bartlett D. 1435 comparison of the cytokine and chemokine secretome of benign and malignant peritoneal fluid identifies FGF and IL 1R alpha as potential drivers of tumor growth. BMJ Specialist Journals; 2022.","DOI":"10.1136\/jitc-2022-SITC2022.1435"},{"key":"5205_CR14","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2023.1157697","volume":"14","author":"VS Donnenberg","year":"2023","unstructured":"Donnenberg VS, Luketich JD, Sultan I, Lister J, Bartlett DL, Ghosh S, et al. A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells. Front Immunol. 2023;14:1299.","journal-title":"Front Immunol"},{"issue":"1","key":"5205_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0590-4","volume":"7","author":"AD Donnenberg","year":"2019","unstructured":"Donnenberg AD, Luketich JD, Dhupar R, Donnenberg VS. Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer. 2019;7(1):1\u20135.","journal-title":"J Immunother Cancer"},{"key":"5205_CR16","doi-asserted-by":"publisher","first-page":"722638","DOI":"10.3389\/fphar.2021.722638","volume":"12","author":"Y Shi","year":"2021","unstructured":"Shi Y, Tao M, Ni J, Tang L, Liu F, Chen H, et al. Requirement of histone deacetylase 6 for interleukin-6 induced epithelial-mesenchymal transition, proliferation, and migration of peritoneal mesothelial cells. Front Pharmacol. 2021;12:722638.","journal-title":"Front Pharmacol"},{"issue":"18","key":"5205_CR17","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","volume":"17","author":"J Coward","year":"2011","unstructured":"Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian CancerIL-6 and ovarian Cancer. Clin Cancer Res. 2011;17(18):6083\u201396.","journal-title":"Clin Cancer Res"},{"key":"5205_CR18","doi-asserted-by":"publisher","first-page":"1157697","DOI":"10.3389\/fimmu.2023.1157697","volume":"14","author":"VS Donnenberg","year":"2023","unstructured":"Donnenberg VS, Luketich JD, Sultan I, Lister J, Bartlett DL, Ghosh S, et al. A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells. Front Immunol. 2023;14:1157697.","journal-title":"Front Immunol"},{"key":"5205_CR19","doi-asserted-by":"publisher","first-page":"846235","DOI":"10.3389\/fimmu.2022.846235","volume":"13","author":"VS Donnenberg","year":"2022","unstructured":"Donnenberg VS, Wagner PL, Luketich JD, Bartlett DL, Donnenberg AD. Localized intra-cavitary therapy to drive systemic anti-tumor immunity. Front Immunol. 2022;13:846235.","journal-title":"Front Immunol"},{"issue":"20","key":"5205_CR20","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.3390\/cancers15205107","volume":"15","author":"CR Lewis","year":"2023","unstructured":"Lewis CR, Dadgar N, Yellin SA, Donnenberg VS, Donnenberg AD, Bartlett DL, et al. Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: emerging strategies to Re-condition a maladaptive Tumor Environment. Cancers. 2023;15(20):5107.","journal-title":"Cancers"},{"key":"5205_CR21","doi-asserted-by":"crossref","unstructured":"Wagner PL, Knotts CM, Donneberg VS, Dadgar N, Pico CC, Xiao K et al. Characterizing the Immune Environment in Peritoneal Carcinomatosis: insights for novel immunotherapy strategies. Ann Surg Oncol. 2023:1\u20139.","DOI":"10.1245\/s10434-023-14553-6"},{"issue":"6","key":"5205_CR22","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/cancers13061352","volume":"13","author":"K Mogi","year":"2021","unstructured":"Mogi K, Yoshihara M, Iyoshi S, Kitami K, Uno K, Tano S, et al. Ovarian cancer-associated mesothelial cells: transdifferentiation to minions of cancer and orchestrate developing peritoneal dissemination. Cancers. 2021;13(6):1352.","journal-title":"Cancers"},{"issue":"5","key":"5205_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12032-023-01987-x","volume":"40","author":"AA El-Arabey","year":"2023","unstructured":"El-Arabey AA, Alkhalil SS, Al-Shouli ST, Awadalla ME, Alhamdi HW, Almanaa TN, et al. Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction. Med Oncol. 2023;40(5):142.","journal-title":"Med Oncol"},{"key":"5205_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3389\/fonc.2019.01267","volume":"9","author":"O Kersy","year":"2019","unstructured":"Kersy O, Loewenstein S, Lubezky N, Sher O, Simon NB, Klausner JM, et al. Omental tissue-mediated tumorigenesis of gastric cancer peritoneal metastases. Front Oncol. 2019;9:1267.","journal-title":"Front Oncol"},{"issue":"2","key":"5205_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/path.4889","volume":"242","author":"A Rynne-Vidal","year":"2017","unstructured":"Rynne-Vidal A, Au\u2010Yeung CL, Jim\u00e9nez\u2010Heffernan JA, P\u00e9rez\u2010Lozano ML, Cremades\u2010Jimeno L, B\u00e1rcena C, et al. Mesothelial\u2010to\u2010mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. J Pathol. 2017;242(2):140\u201351.","journal-title":"J Pathol"},{"issue":"9","key":"5205_CR26","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/17474124.2022.2125866","volume":"16","author":"G-X Wei","year":"2022","unstructured":"Wei G-X, Du Y, Zhou Y-W, Li L-J, Qiu M. Peritoneal carcinomatosis with intraperitoneal immunotherapy: current treatment options and perspectives. Expert Rev Gastroenterol Hepatol. 2022;16(9):851\u201361.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"5205_CR27","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1245\/s10434-020-08591-7","volume":"28","author":"AM Miller","year":"2021","unstructured":"Miller AM, Lemke-Miltner CD, Blackwell S, Tomanek-Chalkley A, Gibson-Corely KN, Coleman KL, et al. Intraperitoneal CMP-001: a novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal and pancreaticobiliary cancer. Ann Surg Oncol. 2021;28:1187\u201397.","journal-title":"Ann Surg Oncol"},{"key":"5205_CR28","doi-asserted-by":"crossref","unstructured":"Forcina L, Franceschi C, Musar\u00f2 A. The hormetic and hermetic role of IL-6. Ageing Res Rev. 2022:101697.","DOI":"10.1016\/j.arr.2022.101697"},{"issue":"1\u20132","key":"5205_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.brainresrev.2011.01.002","volume":"67","author":"A Spooren","year":"2011","unstructured":"Spooren A, Kolmus K, Laureys G, Clinckers R, De Keyser J, Haegeman G, et al. Interleukin-6, a mental cytokine. Brain Res Rev. 2011;67(1\u20132):157\u201383.","journal-title":"Brain Res Rev"},{"issue":"7","key":"5205_CR30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/jpm11070618","volume":"11","author":"C Mart\u00ednez-P\u00e9rez","year":"2021","unstructured":"Mart\u00ednez-P\u00e9rez C, Leung J, Kay C, Meehan J, Gray M, Dixon JM, et al. The signal transducer IL6ST (gp130) as a predictive and prognostic biomarker in breast cancer. J Personalized Med. 2021;11(7):618.","journal-title":"J Personalized Med"},{"issue":"4","key":"5205_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/CS20110340","volume":"122","author":"M Mihara","year":"2012","unstructured":"Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6\/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci. 2012;122(4):143\u201359.","journal-title":"Clin Sci"},{"issue":"2","key":"5205_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/bj3340297","volume":"334","author":"PC Heinrich","year":"1998","unstructured":"Heinrich PC, Behrmann I, M\u00fcller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway. Biochem J. 1998;334(2):297\u2013314.","journal-title":"Biochem J"},{"issue":"3","key":"5205_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/JLB.3MR0621-616RR","volume":"111","author":"Y-D Xu","year":"2022","unstructured":"Xu Y-D, Cheng M, Shang P-P, Yang Y-Q. Role of IL-6 in dendritic cell functions. J Leukoc Biol. 2022;111(3):695\u2013709.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"5205_CR34","doi-asserted-by":"publisher","first-page":"a028415","DOI":"10.1101\/cshperspect.a028415","volume":"10","author":"S Rose-John","year":"2018","unstructured":"Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. 2018;10(2):a028415.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"14","key":"5205_CR35","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.3889\/oamjms.2019.589","volume":"7","author":"DC Chonov","year":"2019","unstructured":"Chonov DC, Ignatova MMK, Ananiev JR, Gulubova MV. IL-6 activities in the tumour microenvironment. Part 1. Open Access Macedonian J Med Sci. 2019;7(14):2391.","journal-title":"Open Access Macedonian J Med Sci"},{"issue":"18","key":"5205_CR36","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","volume":"293","author":"P Baran","year":"2018","unstructured":"Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, et al. The balance of interleukin (IL)-6, IL-6\u00b7 soluble IL-6 receptor (sIL-6R), and IL-6\u00b7 sIL-6R\u00b7 sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem. 2018;293(18):6762\u201375.","journal-title":"J Biol Chem"},{"key":"5205_CR37","doi-asserted-by":"publisher","first-page":"109130","DOI":"10.1016\/j.intimp.2022.109130","volume":"111","author":"M Aliyu","year":"2022","unstructured":"Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, et al. Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol. 2022;111:109130.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"5205_CR38","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.4049\/jimmunol.161.12.6480","volume":"161","author":"EB Samoilova","year":"1998","unstructured":"Samoilova EB, Horton JL, Hilliard B, Liu T-ST, Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol. 1998;161(12):6480\u20136.","journal-title":"J Immunol"},{"issue":"2","key":"5205_CR39","first-page":"1","volume":"8","author":"C Gabay","year":"2006","unstructured":"Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Therapy. 2006;8(2):1\u20136.","journal-title":"Arthritis Res Therapy"},{"issue":"60","key":"5205_CR40","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.18632\/oncotarget.27290","volume":"10","author":"AD Donnenberg","year":"2019","unstructured":"Donnenberg AD, Luketich JD, Donnenberg VS. Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications. Oncotarget. 2019;10(60):6456.","journal-title":"Oncotarget"},{"issue":"11","key":"5205_CR41","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ncb3041","volume":"16","author":"H Lu","year":"2014","unstructured":"Lu H, Clauser KR, Tam WL, Fr\u00f6se J, Ye X, Eaton EN, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16(11):1105\u201317.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"5205_CR42","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.celrep.2015.11.053","volume":"13","author":"M Tang","year":"2015","unstructured":"Tang M, Diao J, Gu H, Khatri I, Zhao J, Cattral MS. Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling. Cell Rep. 2015;13(12):2851\u201364.","journal-title":"Cell Rep"},{"issue":"12","key":"5205_CR43","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"5205_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discovery. 2018;17(6):395\u2013412.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"5205_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/TP.0000000000001452","volume":"101","author":"SC Jordan","year":"2017","unstructured":"Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, et al. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation. 2017;101(1):32\u201344.","journal-title":"Transplantation"},{"issue":"1","key":"5205_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1102\/1470-7330.2011.0016","volume":"11","author":"CM Patel","year":"2011","unstructured":"Patel CM, Sahdev A, Reznek RH. CT, MRI and PET imaging in peritoneal malignancy. Cancer Imaging. 2011;11(1):123.","journal-title":"Cancer Imaging"},{"key":"5205_CR47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00011-019-01247-7","volume":"68","author":"S Katz","year":"2019","unstructured":"Katz S, Zsiros V, Kiss AL. Under inflammatory stimuli mesenteric mesothelial cells transdifferentiate into macrophages and produce pro-inflammatory cytokine IL-6. Inflamm Res. 2019;68:525\u20138.","journal-title":"Inflamm Res"},{"issue":"1","key":"5205_CR48","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ki.1993.36","volume":"43","author":"N Topley","year":"1993","unstructured":"Topley N, J\u00f6rres A, Luttmann W, Petersen MM, Lang MJ, Thierauch K-H, et al. Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1\u03b2 and TNF\u03b1. Kidney Int. 1993;43(1):226\u201333.","journal-title":"Kidney Int"},{"issue":"1","key":"5205_CR49","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/art.24185","volume":"60","author":"WJ Martin","year":"2009","unstructured":"Martin WJ, Walton M, Harper J. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal\u2013induced murine peritoneal model of acute gout. Arthr Rhuem. 2009;60(1):281\u20139.","journal-title":"Arthr Rhuem"},{"key":"5205_CR50","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.2741\/4054","volume":"17","author":"A Camporeale","year":"2012","unstructured":"Camporeale A, Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? Front Biosci. 2012;17:2306\u201326.","journal-title":"Front Biosci"},{"issue":"3","key":"5205_CR51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0015-0282(00)01752-0","volume":"75","author":"A Bergqvist","year":"2001","unstructured":"Bergqvist A, Bruse C, Carlberg M, Carlstr\u00f6m K. Interleukin 1\u03b2, interleukin-6, and tumor necrosis factor-\u03b1 in endometriotic tissue and in endometrium. Fertil Steril. 2001;75(3):489\u201395.","journal-title":"Fertil Steril"},{"issue":"6","key":"5205_CR52","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1074-7613(01)00151-0","volume":"14","author":"SM Hurst","year":"2001","unstructured":"Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14(6):705\u201314.","journal-title":"Immunity"},{"issue":"5","key":"5205_CR53","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.dld.2020.10.025","volume":"53","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Wang J, Huang F, Yao Y, Xu L. Leptin induces NAFLD progression through infiltrated CD8\u2009+\u2009T lymphocytes mediating pyroptotic-like cell death of hepatocytes and macrophages. Dig Liver Disease. 2021;53(5):598\u2013605.","journal-title":"Dig Liver Disease"},{"issue":"1","key":"5205_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2009.08.008","volume":"34","author":"G Tiegs","year":"2010","unstructured":"Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun. 2010;34(1):1\u20136.","journal-title":"J Autoimmun"},{"issue":"1","key":"5205_CR55","doi-asserted-by":"publisher","first-page":"1873585","DOI":"10.1080\/2162402X.2021.1873585","volume":"10","author":"K de Jonge","year":"2021","unstructured":"de Jonge K, Till\u00e9 L, Lourenco J, Maby-El Hajjami H, Nassiri S, Racle J, et al. Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients. Oncoimmunology. 2021;10(1):1873585.","journal-title":"Oncoimmunology"},{"issue":"11","key":"5205_CR56","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1084\/jem.20170580","volume":"214","author":"T Arkatkar","year":"2017","unstructured":"Arkatkar T, Du SW, Jacobs HM, Dam EM, Hou B, Buckner JH, et al. B cell\u2013derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity. J Exp Med. 2017;214(11):3207\u201317.","journal-title":"J Exp Med"},{"issue":"9","key":"5205_CR57","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.molmed.2018.07.004","volume":"24","author":"LK Symons","year":"2018","unstructured":"Symons LK, Miller JE, Kay VR, Marks RM, Liblik K, Koti M, et al. The immunopathophysiology of endometriosis. Trends Mol Med. 2018;24(9):748\u201362.","journal-title":"Trends Mol Med"},{"issue":"3","key":"5205_CR58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127\u201348.","journal-title":"Int Immunol"},{"issue":"10","key":"5205_CR59","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"5205_CR60","doi-asserted-by":"publisher","first-page":"9653","DOI":"10.1074\/jbc.M306662200","volume":"279","author":"X Fang","year":"2004","unstructured":"Fang X, Yu S, Bast RC, Liu S, Xu H-J, Hu S-X, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004;279(10):9653\u201361.","journal-title":"J Biol Chem"},{"issue":"5","key":"5205_CR61","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448\u201357.","journal-title":"Nat Immunol"},{"issue":"8","key":"5205_CR62","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/ndt\/17.8.1480","volume":"17","author":"R Pecoits-Filho","year":"2002","unstructured":"Pecoits-Filho R, Ara\u00fajo MRT, Lindholm B, Stenvinkel P, Abensur H, Rom\u00e3o JE Jr, et al. Plasma and dialysate IL\u20106 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dialysis Transplantation. 2002;17(8):1480\u20136.","journal-title":"Nephrol Dialysis Transplantation"},{"key":"5205_CR63","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s001340051321","volume":"26","author":"A Viallon","year":"2000","unstructured":"Viallon A, Zeni F, Pouzet V, Lambert C, Quenet S, Aubert G, et al. Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines. Intensive Care Med. 2000;26:1082\u20138.","journal-title":"Intensive Care Med"},{"issue":"1","key":"5205_CR64","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1471-4906(02)00013-3","volume":"24","author":"G Kaplanski","year":"2003","unstructured":"Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003;24(1):25\u20139.","journal-title":"Trends Immunol"},{"issue":"2","key":"5205_CR65","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.4049\/jimmunol.1002971","volume":"186","author":"CJ Greenhill","year":"2011","unstructured":"Greenhill CJ, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ, et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol. 2011;186(2):1199\u2013208.","journal-title":"J Immunol"},{"issue":"6","key":"5205_CR66","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3390\/cancers14061415","volume":"14","author":"G Karpathiou","year":"2022","unstructured":"Karpathiou G, P\u00e9oc\u2019h M, Sundaralingam A, Rahman N, Froudarakis ME. Inflammation of the pleural cavity: a review on pathogenesis, diagnosis and implications in tumor pathophysiology. Cancers. 2022;14(6):1415.","journal-title":"Cancers"},{"key":"5205_CR67","volume-title":"Characterisation of ECM protein processing mechanisms underlying simple peritoneal sclerosis and encapsulating","author":"SA Osta Muhammad","year":"2015","unstructured":"Osta Muhammad SA. Characterisation of ECM protein processing mechanisms underlying simple peritoneal sclerosis and encapsulating. peritoneal sclerosis: University of Sheffield; 2015."},{"issue":"10","key":"5205_CR68","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/biom12101498","volume":"12","author":"R Wang","year":"2022","unstructured":"Wang R, Guo T, Li J. Mechanisms of peritoneal mesothelial cells in peritoneal adhesion. Biomolecules. 2022;12(10):1498.","journal-title":"Biomolecules"},{"key":"5205_CR69","unstructured":"Arathimou SA. Characterisation of normal human pleural mesothelium to understand malignant pleural mesothelioma. UCL (University College London); 2020."},{"key":"5205_CR70","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00018-017-2663-1","volume":"75","author":"J Miku\u0142a-Pietrasik","year":"2018","unstructured":"Miku\u0142a-Pietrasik J, Uruski P, Tykarski A, Ksi\u0105\u017cek K. The peritoneal soil for a cancerous seed: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cell Mol Life Sci. 2018;75:509\u201325.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"5205_CR71","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1600-0722.1978.tb00642.x","volume":"86","author":"I Olsen","year":"1978","unstructured":"Olsen I, Bondevik O. Experimental Candida-induced denture stomatitis in the Wistar rat. Eur J Oral Sci. 1978;86(5):392\u20138.","journal-title":"Eur J Oral Sci"},{"issue":"4","key":"5205_CR72","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S0015-0282(16)55881-6","volume":"59","author":"Y-T Lim","year":"1993","unstructured":"Lim Y-T, Schenken RS. Interleukin-6 in experimental endometriosis. Fertil Steril. 1993;59(4):912\u20136.","journal-title":"Fertil Steril"},{"issue":"2","key":"5205_CR73","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0015-0282(16)55216-9","volume":"58","author":"RP Buyalos","year":"1992","unstructured":"Buyalos RP, Funari VA, Azziz R, Watson JM, Martinez-Maza O. Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology. Fertil Steril. 1992;58(2):302\u20136.","journal-title":"Fertil Steril"},{"issue":"7","key":"5205_CR74","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/humrep\/deac098","volume":"37","author":"S Matsuzaki","year":"2022","unstructured":"Matsuzaki S, Pouly J-L, Canis M. Persistent activation of signal transducer and activator of transcription 3 via interleukin-6 trans-signaling is involved in fibrosis of endometriosis. Hum Reprod. 2022;37(7):1489\u2013504.","journal-title":"Hum Reprod"},{"issue":"1","key":"5205_CR75","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Therapy. 2020;5(1):28.","journal-title":"Signal Transduct Target Therapy"},{"key":"5205_CR76","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari N, Dwarakanath B, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biology. 2016;37:11553\u201372.","journal-title":"Tumor Biology"},{"issue":"1","key":"5205_CR77","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"key":"5205_CR78","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.2147\/CMAR.S179189","volume":"10","author":"L Browning","year":"2018","unstructured":"Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manage Res. 2018;10:6685.","journal-title":"Cancer Manage Res"},{"key":"5205_CR79","doi-asserted-by":"crossref","unstructured":"Taniguchi K, Karin M, editors. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in immunology. Elsevier; 2014.","DOI":"10.1016\/j.smim.2014.01.001"},{"issue":"13","key":"5205_CR80","doi-asserted-by":"publisher","first-page":"20741","DOI":"10.18632\/oncotarget.15119","volume":"8","author":"X Wu","year":"2017","unstructured":"Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2\/STAT3 signaling pathway. Oncotarget. 2017;8(13):20741.","journal-title":"Oncotarget"},{"issue":"1","key":"5205_CR81","doi-asserted-by":"publisher","first-page":"8769","DOI":"10.1038\/s41598-017-09333-8","volume":"7","author":"Q Chen","year":"2017","unstructured":"Chen Q, Xu B, Lan L, Yang D, Yang M, Jiang J, et al. High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis. Sci Rep. 2017;7(1):8769.","journal-title":"Sci Rep"},{"issue":"1","key":"5205_CR82","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/0300891618784790","volume":"105","author":"H Yousefi","year":"2019","unstructured":"Yousefi H, Momeny M, Ghaffari SH, Parsanejad N, Poursheikhani A, Javadikooshesh S, et al. IL-6\/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer. Tumori J. 2019;105(1):84\u201391.","journal-title":"Tumori J"},{"issue":"7","key":"5205_CR83","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/07357907.2019.1638395","volume":"37","author":"C Simondurairaj","year":"2019","unstructured":"Simondurairaj C, Krishnakumar R, Sundaram S, Venkatraman G. Interleukin-6 receptor (IL-6R) expression in human gastric carcinoma and its clinical significance. Cancer Invest. 2019;37(7):293\u20138.","journal-title":"Cancer Invest"},{"issue":"3","key":"5205_CR84","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3892\/or.2016.4544","volume":"35","author":"G Zhao","year":"2016","unstructured":"Zhao G, Zhu G, Huang Y, Zheng W, Hua J, Yang S, et al. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer. Oncol Rep. 2016;35(3):1787\u201395.","journal-title":"Oncol Rep"},{"issue":"1","key":"5205_CR85","doi-asserted-by":"publisher","first-page":"38364","DOI":"10.1038\/srep38364","volume":"6","author":"Y Cao","year":"2016","unstructured":"Cao Y, Zhang H, Liu H, Lin C, Li R, Wu S, et al. Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. Sci Rep. 2016;6(1):38364.","journal-title":"Sci Rep"},{"issue":"4","key":"5205_CR86","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1172\/JCI73531","volume":"124","author":"M Rokavec","year":"2014","unstructured":"Rokavec M, \u00d6ner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL-6R\/STAT3\/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Investig. 2014;124(4):1853\u201367.","journal-title":"J Clin Investig"},{"issue":"6","key":"5205_CR87","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/sj.bjc.6605827","volume":"103","author":"Y Okugawa","year":"2010","unstructured":"Okugawa Y, Miki C, Toiyama Y, Yasuda H, Yokoe T, Saigusa S, et al. Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer. Br J Cancer. 2010;103(6):787\u201395.","journal-title":"Br J Cancer"},{"issue":"12","key":"5205_CR88","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.3390\/ijms22126211","volume":"22","author":"P Montero","year":"2021","unstructured":"Montero P, Milara J, Roger I, Cortijo J. Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms. Int J Mol Sci. 2021;22(12):6211.","journal-title":"Int J Mol Sci"},{"key":"5205_CR89","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mrrev.2017.08.003","volume":"774","author":"Q Shi","year":"2017","unstructured":"Shi Q, Godschalk R, Van Schooten F. Inflammation and the chemical carcinogen benzo [a] pyrene: partners in crime. Mutat Research\/Reviews Mutat Res. 2017;774:12\u201324.","journal-title":"Mutat Research\/Reviews Mutat Res"},{"issue":"1","key":"5205_CR90","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2013.12.017","volume":"356","author":"H Klammer","year":"2015","unstructured":"Klammer H, Mladenov E, Li F, Iliakis G. Bystander effects as manifestation of intercellular communication of DNA damage and of the cellular oxidative status. Cancer Lett. 2015;356(1):58\u201371.","journal-title":"Cancer Lett"},{"key":"5205_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01616-9","volume":"39","author":"AR Farina","year":"2020","unstructured":"Farina AR, Cappabianca L, Sebastiano M, Zelli V, Guadagni S, Mackay AR. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. J Experimental Clin Cancer Res. 2020;39:1\u201330.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"4","key":"5205_CR92","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1681\/ASN.2015101169","volume":"28","author":"R Catar","year":"2017","unstructured":"Catar R, Witowski J, Zhu N, L\u00fccht C, Soria AD, Fernandez JU, et al. IL-6 trans\u2013signaling links inflammation with angiogenesis in the peritoneal membrane. J Am Soc Nephrology: JASN. 2017;28(4):1188.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"2","key":"5205_CR93","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/bjc.2013.748","volume":"110","author":"T Nagasaki","year":"2014","unstructured":"Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour\u2013stroma interaction. Br J Cancer. 2014;110(2):469\u201378.","journal-title":"Br J Cancer"},{"issue":"4","key":"5205_CR94","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cellsig.2013.01.007","volume":"25","author":"S-Y Kim","year":"2013","unstructured":"Kim S-Y, Kang JW, Song X, Kim BK, Yoo YD, Kwon YT, et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal. 2013;25(4):961\u20139.","journal-title":"Cell Signal"},{"issue":"20","key":"5205_CR95","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.3390\/cancers14204993","volume":"14","author":"C Maresca","year":"2022","unstructured":"Maresca C, Di Maggio G, Stolfi C, Laudisi F, Colella M, Pacifico T, et al. Smad7 sustains Stat3 expression and signaling in colon cancer cells. Cancers. 2022;14(20):4993.","journal-title":"Cancers"},{"issue":"4","key":"5205_CR96","doi-asserted-by":"publisher","first-page":"e18329","DOI":"10.1371\/journal.pone.0018329","volume":"6","author":"I Bertini","year":"2011","unstructured":"Bertini I, Chevance S, Del Conte R, Lalli D, Turano P. The anti-apoptotic Bcl-xL protein, a new piece in the puzzle of cytochrome c interactome. PLoS ONE. 2011;6(4):e18329.","journal-title":"PLoS ONE"},{"issue":"2","key":"5205_CR97","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/1526-968X(200102)29:2<60::AID-GENE1006>3.0.CO;2-L","volume":"29","author":"JM Kloetzli","year":"2001","unstructured":"Kloetzli JM, Fontaine-Glover IA, Brown ER, Kuo M, Labosky PA. The winged helix gene, Foxb1, controls development of mammary glands and regions of the CNS that regulate the milk\u2010ejection reflex. Genesis. 2001;29(2):60\u201371.","journal-title":"Genesis"},{"key":"5205_CR98","doi-asserted-by":"crossref","unstructured":"Kim J. Regulation of immune cell functions by metabolic reprogramming. Journal of immunology research. 2018;2018.","DOI":"10.1155\/2018\/8605471"},{"issue":"2","key":"5205_CR99","first-page":"254","volume":"21","author":"K Ilkhani","year":"2021","unstructured":"Ilkhani K, Bastami M, Delgir S, Safi A, Talebian S, Alivand M-R. The engaged role of tumor microenvironment in cancer metabolism: focusing on cancer-associated fibroblast and exosome mediators. Anti-Cancer Agents Med Chem (Formerly Curr Med Chemistry-Anti-Cancer Agents). 2021;21(2):254\u201366.","journal-title":"Anti-Cancer Agents Med Chem (Formerly Curr Med Chemistry-Anti-Cancer Agents)"},{"issue":"10","key":"5205_CR100","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1002\/eji.201646618","volume":"46","author":"J Geginat","year":"2016","unstructured":"Geginat J, Paroni M, Kastirr I, Larghi P, Pagani M, Abrignani S. Reverse plasticity: TGF-\u03b2 and IL\u20106 induce Th1\u2010to\u2010Th17\u2010cell transdifferentiation in the gut. Eur J Immunol. 2016;46(10):2306\u201310.","journal-title":"Eur J Immunol"},{"key":"5205_CR101","doi-asserted-by":"crossref","unstructured":"Fisher DT, Appenheimer MM, Evans SS, editors. The two faces of IL-6 in the tumor microenvironment. Seminars in immunology. Elsevier; 2014.","DOI":"10.1016\/j.smim.2014.01.008"},{"issue":"3","key":"5205_CR102","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.immuni.2017.03.010","volume":"46","author":"JJ Goronzy","year":"2017","unstructured":"Goronzy JJ, Weyand CM. Successful and maladaptive T cell aging. Immunity. 2017;46(3):364\u201378.","journal-title":"Immunity"},{"issue":"6","key":"5205_CR103","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/82763","volume":"1","author":"P Chomarat","year":"2000","unstructured":"Chomarat P, Banchereau J, Davoust J, Karolina Palucka A. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000;1(6):510\u20134.","journal-title":"Nat Immunol"},{"issue":"1","key":"5205_CR104","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ctrv.2012.07.003","volume":"39","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev. 2013;39(1):89\u201396.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"5205_CR105","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/diagnostics11091625","volume":"11","author":"W Pawlik","year":"2021","unstructured":"Pawlik W, Pawlik J, Koz\u0142owski M, \u0141uczkowska K, Kwiatkowski S, Kwiatkowska E, et al. The clinical importance of IL-6, IL-8, and TNF-\u03b1 in patients with ovarian carcinoma and Benign cystic lesions. Diagnostics. 2021;11(9):1625.","journal-title":"Diagnostics"},{"issue":"7","key":"5205_CR106","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.3390\/ijms24076650","volume":"24","author":"Y-H Huang","year":"2023","unstructured":"Huang Y-H, Chen H-K, Hsu Y-F, Chen H-C, Chuang C-H, Huang S-W, et al. Src-FAK signaling mediates interleukin 6-Induced HCT116 colorectal Cancer epithelial\u2013mesenchymal transition. Int J Mol Sci. 2023;24(7):6650.","journal-title":"Int J Mol Sci"},{"key":"5205_CR107","doi-asserted-by":"crossref","unstructured":"Wertel I, Suszczyk D, Paw\u0142owska A, Bilska M, Chudzik A, Skiba W et al. Prognostic and clinical value of interleukin 6 and CD45\u2009+\u2009CD14\u2009+\u2009inflammatory cells with PD-L1+\/PD-L2\u2009+\u2009expression in patients with different manifestation of ovarian cancer. Journal of Immunology Research. 2020;2020.","DOI":"10.1155\/2020\/1715064"},{"issue":"10","key":"5205_CR108","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ymthe.2019.05.017","volume":"27","author":"K Xu","year":"2019","unstructured":"Xu K, Zhan Y, Yuan Z, Qiu Y, Wang H, Fan G, et al. Hypoxia induces drug resistance in colorectal cancer through the HIF-1\u03b1\/miR-338-5p\/IL-6 feedback loop. Mol Ther. 2019;27(10):1810\u201324.","journal-title":"Mol Ther"},{"key":"5205_CR109","doi-asserted-by":"crossref","unstructured":"Alubaidi GT, Humadi YA, Hamoodi DA, Mahdi HT, Anid BA, Jasim IA et al. Serum interleukin-6 is associated with hypocalcemia, hypoferritinemia and hyperkalemia in end-stage renal disease patients. Italian J Med. 2022;16(1).","DOI":"10.4081\/itjm.2022.1550"},{"issue":"5","key":"5205_CR110","doi-asserted-by":"publisher","first-page":"792","DOI":"10.7150\/jca.22656","volume":"9","author":"X Ding","year":"2018","unstructured":"Ding X, Zhang J, Liu D, Xu W, Lu D-y, Zhang L-P, et al. Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients. J Cancer. 2018;9(5):792.","journal-title":"J Cancer"},{"issue":"25","key":"5205_CR111","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.2174\/138161212802002797","volume":"18","author":"M Dijkgraaf","year":"2012","unstructured":"Dijkgraaf M, JP Welters E, Nortier MWR, van der Burg JH, Kroep SR. Interleukin-6\/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Design. 2012;18(25):3816\u201327.","journal-title":"Curr Pharm Design"},{"key":"5205_CR112","doi-asserted-by":"publisher","first-page":"156073","DOI":"10.1016\/j.cyto.2022.156073","volume":"161","author":"A Pa\u0219ca","year":"2023","unstructured":"Pa\u0219ca A, Fischer-Fodor E, Jiboc NM, Kubelac PM, Saha B, Vlad C, et al. Meta-analyses reveal serum or plasma Interleukin-6 as a biomarker for malignant ovarian neoplasia. Cytokine. 2023;161:156073.","journal-title":"Cytokine"},{"key":"5205_CR113","doi-asserted-by":"crossref","unstructured":"Zhang T, Yang J, Sun Y, Song J, Gao D, Huang S et al. Interleukin-6 and Hypoxia Synergistically Promote EMT-Mediated Invasion in Epithelial Ovarian Cancer via the IL-6\/STAT3\/HIF-1\u03b1 Feedback Loop. Analytical Cellular Pathology. 2023;2023.","DOI":"10.1155\/2023\/8334881"},{"issue":"1","key":"5205_CR114","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","volume":"12","author":"EH Bent","year":"2021","unstructured":"Bent EH, Mill\u00e1n-Barea LR, Zhuang I, Goulet DR, Fr\u00f6se J, Hemann MT. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Nat Commun. 2021;12(1):6218.","journal-title":"Nat Commun"},{"issue":"3","key":"5205_CR115","doi-asserted-by":"publisher","first-page":"e15914","DOI":"10.15252\/emmm.202215914","volume":"15","author":"S Bootsma","year":"2023","unstructured":"Bootsma S, Bijlsma MF, Vermeulen L. The molecular biology of peritoneal metastatic disease. EMBO Mol Med. 2023;15(3):e15914.","journal-title":"EMBO Mol Med"},{"key":"5205_CR116","doi-asserted-by":"crossref","unstructured":"Rathod S. T cells in the peritoneum. International Review of Cell and Molecular Biology. 371: Elsevier; 2022. pp. 15\u201341.","DOI":"10.1016\/bs.ircmb.2022.04.013"},{"key":"5205_CR117","doi-asserted-by":"crossref","unstructured":"Gelberg HB. Alimentary system and the peritoneum, omentum, mesentery, and peritoneal cavity. Pathologic Basis Veterinary Disease. 2017:324.","DOI":"10.1016\/B978-0-323-35775-3.00007-2"},{"issue":"1","key":"5205_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-11-210","volume":"11","author":"D Lane","year":"2011","unstructured":"Lane D, Matte I, Rancourt C, Pich\u00e9 A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11(1):1\u20136.","journal-title":"BMC Cancer"},{"key":"5205_CR119","doi-asserted-by":"crossref","unstructured":"Yang J, Cao W, Xing E. Levels and Significance of Tumor Markers and Cytokines in Serum and Peritoneal Lavage Fluid of Patients with Peritoneal Metastasis of Gastric Cancer. BioMed Research International. 2022;2022.","DOI":"10.1155\/2022\/9528444"},{"issue":"1","key":"5205_CR120","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0304-3835(99)00401-2","volume":"151","author":"MR Schneider","year":"2000","unstructured":"Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 2000;151(1):31\u20138.","journal-title":"Cancer Lett"},{"key":"5205_CR121","doi-asserted-by":"crossref","unstructured":"Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manage Res. 2018:6685\u201393.","DOI":"10.2147\/CMAR.S179189"},{"issue":"18","key":"5205_CR122","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","volume":"17","author":"J Coward","year":"2011","unstructured":"Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011;17(18):6083\u201396.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5205_CR123","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12634","volume":"282","author":"K Mukai","year":"2018","unstructured":"Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018;282(1):121\u201350.","journal-title":"Immunol Rev"},{"key":"5205_CR124","doi-asserted-by":"crossref","unstructured":"Wilson RB. Hypoxia, cytokines and stromal recruitment: parallels between pathophysiology of encapsulating peritoneal sclerosis, endometriosis and peritoneal metastasis. Pleura Peritoneum. 2018;3(1).","DOI":"10.1515\/pp-2018-0103"},{"issue":"5","key":"5205_CR125","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1111\/j.1755-5922.2010.00171.x","volume":"28","author":"M Cesari","year":"2010","unstructured":"Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI\u20101): a key factor linking fibrinolysis and age\u2010related subclinical and clinical conditions. Cardiovasc Ther. 2010;28(5):e72\u201391.","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"5205_CR126","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41389-020-0209-0","volume":"9","author":"MK Siu","year":"2020","unstructured":"Siu MK, Jiang Y-x, Wang J-j, Leung TH, Ngu SF, Cheung AN, et al. PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via \u03b15\u03b21 integrin and JNK\/IL-8 signaling. Oncogenesis. 2020;9(2):24.","journal-title":"Oncogenesis"},{"issue":"1","key":"5205_CR127","doi-asserted-by":"publisher","first-page":"298","DOI":"10.7150\/ijbs.54403","volume":"17","author":"Q Hu","year":"2021","unstructured":"Hu Q, Xia X, Kang X, Song P, Liu Z, Wang M, et al. A review of physiological and cellular mechanisms underlying fibrotic postoperative adhesion. Int J Biol Sci. 2021;17(1):298\u2013306.","journal-title":"Int J Biol Sci"},{"key":"5205_CR128","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jss.2022.02.005","volume":"275","author":"IISP Carmichael","year":"2022","unstructured":"Carmichael IISP, Shin J, Vaughan JW, Chandra PK, Holcomb JB, Atala AJ. Regenerative Medicine Therapies for Prevention of Abdominal adhesions: a scoping review. J Surg Res. 2022;275:252\u201364.","journal-title":"J Surg Res"},{"issue":"9","key":"5205_CR129","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.4049\/jimmunol.161.9.4992","volume":"161","author":"J-W Oh","year":"1998","unstructured":"Oh J-W, Van Wagoner NJ, Rose-John S, Benveniste EN. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression. J Immunol. 1998;161(9):4992\u20139.","journal-title":"J Immunol"},{"key":"5205_CR130","doi-asserted-by":"publisher","first-page":"e1131","DOI":"10.1016\/j.wneu.2019.05.102","volume":"128","author":"R Rasmussen","year":"2019","unstructured":"Rasmussen R, Bache S, Stavngaard T, M\u00f8ller K. Plasma levels of IL-6, IL-8, IL-10, ICAM-1, VCAM-1, IFN\u03b3, and TNF\u03b1 are not associated with delayed cerebral ischemia, cerebral vasospasm, or clinical outcome in patients with subarachnoid hemorrhage. World Neurosurg. 2019;128:e1131\u20136.","journal-title":"World Neurosurg"},{"key":"5205_CR131","first-page":"447","volume":"36","author":"P Wu","year":"2021","unstructured":"Wu P, Wang J, Mao X, Xu H, Zhu Z. PDCD4 regulates apoptosis in human peritoneal mesothelial cells and promotes gastric cancer peritoneal metastasis. Histol Histopathol. 2021;36:447\u201357.","journal-title":"Histol Histopathol"},{"issue":"6","key":"5205_CR132","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1515\/hsz-2021-0120","volume":"402","author":"H Yang","year":"2021","unstructured":"Yang H, Xu W. STAT3 promotes peritoneal metastasis of gastric cancer by enhancing mesothelial-mesenchymal transition. Biol Chem. 2021;402(6):739\u201348.","journal-title":"Biol Chem"},{"key":"5205_CR133","doi-asserted-by":"crossref","unstructured":"Bajwa P, Kordylewicz K, Bilecz A, Lastra RR, Wroblewski K, Rinkevich Y et al. Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis. JCI Insight. 2023.","DOI":"10.1172\/jci.insight.163019"},{"issue":"1","key":"5205_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11658-021-00296-3","volume":"26","author":"M Tian","year":"2021","unstructured":"Tian M, Tang Y, Huang T, Liu Y, Pan Y. Amelioration of human peritoneal mesothelial cell co-culture-evoked malignant potential of ovarian cancer cells by acacetin involves LPA release-activated RAGE-PI3K\/AKT signaling. Cell Mol Biol Lett. 2021;26(1):1\u201312.","journal-title":"Cell Mol Biol Lett"},{"issue":"3","key":"5205_CR135","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12016-019-08753-w","volume":"58","author":"DEA Komi","year":"2020","unstructured":"Komi DEA, Redegeld FA. Role of mast cells in shaping the tumor microenvironment. Clin Rev Allergy Immunol. 2020;58(3):313\u201325.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"5205_CR136","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.3390\/ijms23116215","volume":"23","author":"M Rakina","year":"2022","unstructured":"Rakina M, Kazakova A, Villert A, Kolomiets L, Larionova I. Spheroid formation and peritoneal metastasis in ovarian cancer: the role of stromal and immune components. Int J Mol Sci. 2022;23(11):6215.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5205_CR137","doi-asserted-by":"publisher","first-page":"188639","DOI":"10.1016\/j.bbcan.2021.188639","volume":"1876","author":"I Szulc-Kielbik","year":"2021","unstructured":"Szulc-Kielbik I, Kielbik M, Nowak M, Klink M. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2021;1876(2):188639.","journal-title":"Biochim et Biophys Acta (BBA)-Reviews Cancer"},{"issue":"1","key":"5205_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-022-02527-9","volume":"22","author":"N Radharani","year":"2022","unstructured":"Radharani N, Yadav AS, Nimma R, Kumar T, Bulbule A, Chanukuppa V, et al. Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer Cell Int. 2022;22(1):1\u201319.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"5205_CR139","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/0960327120964543","volume":"40","author":"A Karamian","year":"2021","unstructured":"Karamian A, Paktinat S, Esfandyari S, Nazarian H, Ziai SA, Zarnani A-H, et al. Pyrvinium pamoate induces in-vitro suppression of IL-6 and IL-8 produced by human endometriotic stromal cells. Hum Exp Toxicol. 2021;40(4):649\u201360.","journal-title":"Hum Exp Toxicol"},{"issue":"4","key":"5205_CR140","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/cancers13040658","volume":"13","author":"M Vogl","year":"2021","unstructured":"Vogl M, Rosenmayr A, Bohanes T, Scheed A, Brndiar M, Stubenberger E, et al. Biomarkers for malignant pleural mesothelioma\u2014A novel view on inflammation. Cancers. 2021;13(4):658.","journal-title":"Cancers"},{"issue":"1","key":"5205_CR141","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Therapy. 2021;6(1):263.","journal-title":"Signal Transduct Target Therapy"},{"issue":"5","key":"5205_CR142","doi-asserted-by":"publisher","first-page":"651","DOI":"10.7150\/ijbs.7.651","volume":"7","author":"BF Zamarron","year":"2011","unstructured":"Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"5205_CR143","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1158\/2326-6066.CIR-13-0030","volume":"1","author":"H Tsukamoto","year":"2013","unstructured":"Tsukamoto H, Nishikata R, Senju S, Nishimura Y. Myeloid-derived suppressor cells attenuate TH1 Development through IL-6 production to promote Tumor ProgressionDampening of Antitumor TH1 Development by MDSC-Derived IL-6. Cancer Immunol Res. 2013;1(1):64\u201376.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"5205_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.07.004","volume":"66","author":"P Allavena","year":"2008","unstructured":"Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol\/Hematol. 2008;66(1):1\u20139.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"5205_CR145","doi-asserted-by":"publisher","first-page":"693517","DOI":"10.3389\/fonc.2021.693517","volume":"11","author":"Y Tan","year":"2021","unstructured":"Tan Y, Wang M, Zhang Y, Ge S, Zhong F, Xia G, et al. Tumor-associated macrophages: a potential target for cancer therapy. Front Oncol. 2021;11:693517.","journal-title":"Front Oncol"},{"key":"5205_CR146","doi-asserted-by":"crossref","unstructured":"Cui Q, Li L, Hu Y, Wang F, Zhang C, Li C. Effects of stress response induced by laparoscopic colectomy and laparotomy on TLR-mediated innate immune responses in colon cancer patients. Oncologie. 2023(0).","DOI":"10.1515\/oncologie-2022-1012"},{"key":"5205_CR147","doi-asserted-by":"crossref","unstructured":"Kumar N, Vyas A, Agnihotri SK, Chattopadhyay N, Sachdev M, editors. Small secretory proteins of immune cells can modulate gynecological cancers. Seminars in Cancer Biology; 2022: Elsevier.","DOI":"10.1016\/j.semcancer.2022.02.008"},{"issue":"8","key":"5205_CR148","first-page":"555","volume":"25","author":"SM Kamal","year":"2022","unstructured":"Kamal SM, Mohamed SA-B, Fares KM, Abdelemam RM, Elmasry HM, Mansour S. Immunosuppressive effect of Intrathecal Morphine, Dexmedetomidine, or both in combination with bupivacaine on patients undergoing major abdominal Cancer surgery. Pain Physician. 2022;25(8):555.","journal-title":"Pain Physician"},{"key":"5205_CR149","doi-asserted-by":"crossref","unstructured":"Vrieling F, Stienstra R. Obesity and dysregulated innate immune responses: impact of micronutrient deficiencies. Trends Immunol. 2023.","DOI":"10.1016\/j.it.2023.01.003"},{"issue":"2suppl","key":"5205_CR150","first-page":"S1","volume":"2","author":"E Choy","year":"2017","unstructured":"Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. J Scleroderma Relat Disorders. 2017;2(2suppl):S1\u20135.","journal-title":"J Scleroderma Relat Disorders"},{"key":"5205_CR151","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-pathol-042220-023633","volume":"18","author":"C Auger","year":"2023","unstructured":"Auger C, Kajimura S. Adipose tissue remodeling in pathophysiology. Annu Rev Pathol. 2023;18:71\u201393.","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"5205_CR152","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1038\/oncsis.2016.3","volume":"5","author":"P Porporato","year":"2016","unstructured":"Porporato P. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016;5(2):e200\u2013e.","journal-title":"Oncogenesis"},{"issue":"7\u20138","key":"5205_CR153","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00011-022-01586-y","volume":"71","author":"R Nogueira-Ferreira","year":"2022","unstructured":"Nogueira-Ferreira R, Sousa-Nunes F, Leite-Moreira A, Moreira-Costa L, Vitorino R, Lara Santos L, et al. Cancer-and cardiac-induced cachexia: same fate through different inflammatory mediators? Inflamm Res. 2022;71(7\u20138):771\u201383.","journal-title":"Inflamm Res"},{"key":"5205_CR154","doi-asserted-by":"crossref","unstructured":"Jengelley DH, Zimmers TA. The role of Interleukin-6\/GP130 cytokines in Cancer Cachexia. The systemic effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia. Springer; 2022. pp. 97\u2013117.","DOI":"10.1007\/978-3-031-09518-4_6"},{"key":"5205_CR155","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1385\/IR:23:1:41","volume":"23","author":"BE Barton","year":"2001","unstructured":"Barton BE. IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. Immunol Res. 2001;23:41\u201358.","journal-title":"Immunol Res"},{"key":"5205_CR156","doi-asserted-by":"crossref","unstructured":"Bhardwaj V, Zhang X, Pandey V, Garg M. Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2023:188888.","DOI":"10.1016\/j.bbcan.2023.188888"},{"issue":"4","key":"5205_CR157","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3892\/ijo.2014.2259","volume":"44","author":"S-W Wang","year":"2014","unstructured":"Wang S-W, Sun Y-M. The IL-6\/JAK\/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer. Int J Oncol. 2014;44(4):1032\u201340.","journal-title":"Int J Oncol"},{"issue":"9","key":"5205_CR158","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","volume":"13","author":"M Sheppard","year":"2017","unstructured":"Sheppard M, Laskou F, Stapleton P, Hadavi S, Dasgupta B. Tocilizumab (actemra). Hum Vaccines Immunotherapeutics. 2017;13(9):1972\u201388.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"5205_CR159","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","volume":"93","author":"C Campochiaro","year":"2021","unstructured":"Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, et al. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med. 2021;93:87\u201394.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"5205_CR160","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/1078-0432.CCR-14-1678","volume":"21","author":"A Deisseroth","year":"2015","unstructured":"Deisseroth A, Ko C-W, Nie L, Zirkelbach JF, Zhao L, Bullock J, et al. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res. 2015;21(5):950\u20134.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"5205_CR161","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-10-1095","volume":"16","author":"Y Guo","year":"2010","unstructured":"Guo Y, Nemeth J, O\u2019Brien C, Susa M, Liu X, Zhang Z, et al. Effects of Siltuximab on the IL-6\u2013Induced Signaling Pathway in Ovarian Cancer. Clin Cancer Res. 2010;16(23):5759\u201369.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5205_CR162","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/cpdd.121","volume":"3","author":"K Kretsos","year":"2014","unstructured":"Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, et al. Safety and pharmacokinetics of olokizumab, an anti-IL\u20106 monoclonal antibody, administered to healthy male volunteers: a randomized phase I study. Clin Pharmacol Drug Dev. 2014;3(5):388\u201395.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"23","key":"5205_CR163","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","volume":"15","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, et al. A high-affinity fully human anti\u2013IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009;15(23):7144\u201352.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"5205_CR164","doi-asserted-by":"publisher","first-page":"15460","DOI":"10.18632\/oncotarget.7102","volume":"7","author":"T-H Heo","year":"2016","unstructured":"Heo T-H, Wahler J, Suh N. Potential therapeutic implications of IL-6\/IL-6R\/gp130-targeting agents in breast cancer. Oncotarget. 2016;7(13):15460.","journal-title":"Oncotarget"},{"issue":"5","key":"5205_CR165","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/17512433.2022.2097905","volume":"15","author":"M Narazaki","year":"2022","unstructured":"Narazaki M, Kishimoto T. Current status and prospects of IL-6\u2013targeting therapy. Expert Rev Clin Pharmacol. 2022;15(5):575\u201392.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"5205_CR166","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1677\/ERC-09-0200","volume":"17","author":"FR Santer","year":"2010","unstructured":"Santer FR, Malinowska K, Culig Z, Cavarretta IT. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocrine-related Cancer. 2010;17(1):241.","journal-title":"Endocrine-related Cancer"},{"key":"5205_CR167","doi-asserted-by":"crossref","unstructured":"Chen Y, Zhou J, Xu S, Nie J. Role of IL-6 family cytokines in organ fibrosis. Kidney Dis. 2023.","DOI":"10.1159\/000530288"},{"issue":"4","key":"5205_CR168","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007\u201323.","journal-title":"Immunity"},{"issue":"1","key":"5205_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-023-02854-5","volume":"23","author":"S Mei","year":"2023","unstructured":"Mei S, Chen X, Wang K, Chen Y. Tumor microenvironment in ovarian cancer peritoneal metastasis. Cancer Cell Int. 2023;23(1):1\u201313.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"5205_CR170","doi-asserted-by":"publisher","first-page":"e0118080","DOI":"10.1371\/journal.pone.0118080","volume":"10","author":"A Isobe","year":"2015","unstructured":"Isobe A, Sawada K, Kinose Y, Ohyagi-Hara C, Nakatsuka E, Makino H, et al. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS ONE. 2015;10(2):e0118080.","journal-title":"PLoS ONE"},{"key":"5205_CR171","doi-asserted-by":"crossref","unstructured":"Ruan J, Zhang P, Zhang Q, Zhao S, Dang Z, Lu M et al. Colorectal cancer inhibitory properties of polysaccharides and their molecular mechanisms: a review. Int J Biol Macromol. 2023:124165.","DOI":"10.1016\/j.ijbiomac.2023.124165"},{"issue":"1","key":"5205_CR172","doi-asserted-by":"publisher","first-page":"17558","DOI":"10.1038\/s41598-019-54175-1","volume":"9","author":"N Uyama","year":"2019","unstructured":"Uyama N, Tsutsui H, Wu S, Yasuda K, Hatano E, Qin X-Y, et al. Anti-interleukin-6 receptor antibody treatment ameliorates postoperative adhesion formation. Sci Rep. 2019;9(1):17558.","journal-title":"Sci Rep"},{"issue":"2","key":"5205_CR173","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/0008-5472.CAN-10-1496","volume":"71","author":"C-W Lo","year":"2011","unstructured":"Lo C-W, Chen M-W, Hsiao M, Wang S, Chen C-A, Hsiao S-M, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011;71(2):424\u201334.","journal-title":"Cancer Res"},{"issue":"17","key":"5205_CR174","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","volume":"15","author":"S Shinriki","year":"2009","unstructured":"Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 2009;15(17):5426\u201334.","journal-title":"Clin Cancer Res"},{"key":"5205_CR175","doi-asserted-by":"publisher","first-page":"156271","DOI":"10.1016\/j.cyto.2023.156271","volume":"169","author":"M Zhou","year":"2023","unstructured":"Zhou M, Na R, Lai S, Guo Y, Shi J, Nie J, et al. The present roles and future perspectives of Interleukin-6 in biliary tract cancer. Cytokine. 2023;169:156271.","journal-title":"Cytokine"},{"issue":"3","key":"5205_CR176","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3390\/ijms23031809","volume":"23","author":"CM Felcher","year":"2022","unstructured":"Felcher CM, Bogni ES, Kordon EC. IL-6 cytokine family: a putative target for breast cancer prevention and treatment. Int J Mol Sci. 2022;23(3):1809.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"5205_CR177","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.3390\/cancers14215262","volume":"14","author":"G Clamon","year":"2022","unstructured":"Clamon G, Byrne MM, Talbert EE. Inflammation as a therapeutic target in cancer cachexia. Cancers. 2022;14(21):5262.","journal-title":"Cancers"},{"issue":"5","key":"5205_CR178","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2022.04.010","volume":"40","author":"J Delyon","year":"2022","unstructured":"Delyon J, Lebbe C. IL-6 blockade in cancer patients treated with immune checkpoint blockade: a win-win strategy. Cancer Cell. 2022;40(5):450\u20131.","journal-title":"Cancer Cell"},{"issue":"21","key":"5205_CR179","first-page":"6959","volume":"50","author":"JM Watson","year":"1990","unstructured":"Watson JM, Sensintaffar JL, Berek JS, Mart\u00ednez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990;50(21):6959\u201365.","journal-title":"Cancer Res"},{"issue":"1","key":"5205_CR180","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1006\/gyno.1993.1077","volume":"49","author":"JM Watson","year":"1993","unstructured":"Watson JM, Berek JS, Mart\u0131\u0301nez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol. 1993;49(1):8\u201315.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"5205_CR181","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R","volume":"73","author":"M Plante","year":"1994","unstructured":"Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 1994;73(7):1882\u20138.","journal-title":"Cancer"},{"issue":"2","key":"5205_CR182","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/bjc.1995.71","volume":"71","author":"G Scambia","year":"1995","unstructured":"Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71(2):354\u20136.","journal-title":"Br J Cancer"},{"issue":"8","key":"5205_CR183","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","volume":"17","author":"MS Anglesio","year":"2011","unstructured":"Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17(8):2538\u201348.","journal-title":"Clin Cancer Res"},{"key":"5205_CR184","doi-asserted-by":"crossref","unstructured":"Wang Y, Zong X, Mitra S, Mitra AK, Matei D, Nephew KP. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. JCI Insight. 2018;3(23).","DOI":"10.1172\/jci.insight.122360"},{"issue":"37","key":"5205_CR185","doi-asserted-by":"publisher","first-page":"40005","DOI":"10.18632\/oncotarget.5552","volume":"6","author":"V Rohnalter","year":"2015","unstructured":"Rohnalter V, Roth K, Finkernagel F, Adhikary T, Obert J, Dorzweiler K, et al. A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget. 2015;6(37):40005.","journal-title":"Oncotarget"},{"issue":"42","key":"5205_CR186","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1038\/s41388-020-01451-4","volume":"39","author":"C Mehner","year":"2020","unstructured":"Mehner C, Miller E, Hockla A, Coban M, Weroha SJ, Radisky DC, et al. Targeting an autocrine IL-6\u2013SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. Oncogene. 2020;39(42):6606\u201318.","journal-title":"Oncogene"},{"issue":"7","key":"5205_CR187","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1110352","volume":"366","author":"RL Stone","year":"2012","unstructured":"Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"5205_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0787-z","volume":"17","author":"J Pasquier","year":"2018","unstructured":"Pasquier J, Gosset M, Geyl C, Hoarau-V\u00e9chot J, Chevrot A, Pocard M, et al. CCL2\/CCL5 secreted by the stroma induce IL-6\/PYK2 dependent chemoresistance in ovarian cancer. Mol Cancer. 2018;17(1):1\u201314.","journal-title":"Mol Cancer"},{"issue":"7","key":"5205_CR189","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.3390\/ijms24076038","volume":"24","author":"S-A Park","year":"2023","unstructured":"Park S-A, Seo YJ, Kim LK, Kim HJ, Yoon KD, Heo T-H. Butein inhibits cell growth by blocking the IL-6\/IL-6R\u03b1 Interaction in Human Ovarian Cancer and by regulation of the IL-6\/STAT3\/FoxO3a pathway. Int J Mol Sci. 2023;24(7):6038.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5205_CR190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2022.5340","volume":"60","author":"R Zhang","year":"2022","unstructured":"Zhang R, Roque DM, Reader J, Lin J. Combined inhibition of IL\u20136 and IL\u20138 pathways suppresses ovarian cancer cell viability and migration and tumor growth. Int J Oncol. 2022;60(5):1\u20139.","journal-title":"Int J Oncol"},{"issue":"10","key":"5205_CR191","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","volume":"26","author":"E Dijkgraaf","year":"2015","unstructured":"Dijkgraaf E, Santegoets S, Reyners A, Goedemans R, Wouters M, Kenter G, et al. A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer. Ann Oncol. 2015;26(10):2141\u20139.","journal-title":"Ann Oncol"},{"issue":"8","key":"5205_CR192","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1158\/1078-0432.CCR-13-2200","volume":"20","author":"E Angevin","year":"2014","unstructured":"Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, Van Laethem J-L, et al. A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014;20(8):2192\u2013204.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5205_CR193","first-page":"301","volume":"33","author":"C-C Chang","year":"2010","unstructured":"Chang C-C, Sun C-F, Pai H-J, Wang W-K, Hsieh C-C, Kuo L-M, et al. Preoperative serum C-reactive protein and gastric cancer; clinical-pathological correlation and prognostic significance. Chang Gung Med J. 2010;33(3):301\u201312.","journal-title":"Chang Gung Med J"},{"key":"5205_CR194","doi-asserted-by":"publisher","first-page":"173107","DOI":"10.1016\/j.ejphar.2020.173107","volume":"878","author":"T Gharibi","year":"2020","unstructured":"Gharibi T, Babaloo Z, Hosseini A, Abdollahpour-Alitappeh M, Hashemi V, Marofi F, et al. Targeting STAT3 in cancer and autoimmune diseases. Eur J Pharmacol. 2020;878:173107.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"5205_CR195","doi-asserted-by":"publisher","first-page":"e60914","DOI":"10.1371\/journal.pone.0060914","volume":"8","author":"H Kinoshita","year":"2013","unstructured":"Kinoshita H, Hirata Y, Nakagawa H, Sakamoto K, Hayakawa Y, Takahashi R, et al. Interleukin-6 mediates epithelial\u2013stromal interactions and promotes gastric tumorigenesis. PLoS ONE. 2013;8(4):e60914.","journal-title":"PLoS ONE"},{"issue":"1","key":"5205_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-155","volume":"9","author":"D-K Kim","year":"2009","unstructured":"Kim D-K, Oh SY, Kwon H-C, Lee S, Kwon KA, Kim BG, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009;9(1):1\u20139.","journal-title":"BMC Cancer"},{"issue":"1","key":"5205_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-357","volume":"14","author":"A Ruzzo","year":"2014","unstructured":"Ruzzo A, Catalano V, Canestrari E, Giacomini E, Santini D, Tonini G, et al. Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy. BMC Cancer. 2014;14(1):1\u20138.","journal-title":"BMC Cancer"},{"key":"5205_CR198","doi-asserted-by":"crossref","unstructured":"Zhang Z, Weng B, Qiu Y, Feng H, Zhang R, Zhang J et al. Effect of Perioperative Interleukin-6 and Tumor Necrosis factor-on Long-Term outcomes in locally advanced gastric Cancer: results from the CLASS-01 trial. J Immunol Res. 2022.","DOI":"10.1155\/2022\/7863480"},{"issue":"6","key":"5205_CR199","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.3892\/ol.2017.6073","volume":"13","author":"D Wang","year":"2017","unstructured":"Wang D, Tang S, Zhang Q. Maslinic acid suppresses the growth of human gastric cells by inducing apoptosis via inhibition of the interleukin-6 mediated Janus kinase\/signal transducer and activator of transcription 3 signaling pathway. Oncol Lett. 2017;13(6):4875\u201381.","journal-title":"Oncol Lett"},{"issue":"3","key":"5205_CR200","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.trecan.2019.12.008","volume":"6","author":"W Ceelen","year":"2020","unstructured":"Ceelen W, Ramsay RG, Narasimhan V, Heriot AG, De Wever O. Targeting the tumor microenvironment in colorectal peritoneal metastases. Trends cancer. 2020;6(3):236\u201346.","journal-title":"Trends cancer"},{"issue":"2","key":"5205_CR201","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","volume":"15","author":"S Grivennikov","year":"2009","unstructured":"Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15(2):103\u201313.","journal-title":"Cancer Cell"},{"issue":"2","key":"5205_CR202","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2009.01.002","volume":"15","author":"J Bollrath","year":"2009","unstructured":"Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15(2):91\u2013102.","journal-title":"Cancer Cell"},{"issue":"9","key":"5205_CR203","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.7150\/ijbs.4614","volume":"8","author":"MJ Waldner","year":"2012","unstructured":"Waldner MJ, Foersch S, Neurath MF. Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci. 2012;8(9):1248.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"5205_CR204","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41419-017-0176-3","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, Hu F, Li G, Li G, Yang X, Liu L, et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6\/JAK2\/STAT3 signaling. Cell Death Dis. 2018;9(2):25.","journal-title":"Cell Death Dis"},{"issue":"1","key":"5205_CR205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-0976-4","volume":"18","author":"C Wei","year":"2019","unstructured":"Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18(1):1\u201323.","journal-title":"Mol Cancer"},{"issue":"9","key":"5205_CR206","doi-asserted-by":"publisher","first-page":"6359","DOI":"10.1002\/jcp.26433","volume":"233","author":"Y Sun","year":"2018","unstructured":"Sun Y, Wang R, Qiao M, Xu Y, Guan W, Wang L. Cancer associated fibroblasts tailored tumor microenvironment of therapy resistance in gastrointestinal cancers. J Cell Physiol. 2018;233(9):6359\u201369.","journal-title":"J Cell Physiol"},{"key":"5205_CR207","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s10495-018-1460-0","volume":"23","author":"S Li","year":"2018","unstructured":"Li S, Tian J, Zhang H, Zhou S, Wang X, Zhang L, et al. Down-regulating IL-6\/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer. Apoptosis. 2018;23:356\u201374.","journal-title":"Apoptosis"},{"issue":"23","key":"5205_CR208","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-17-1283","volume":"23","author":"Y Yin","year":"2017","unstructured":"Yin Y, Yao S, Hu Y, Feng Y, Li M, Bian Z, et al. The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6. Clin Cancer Res. 2017;23(23):7375\u201387.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5205_CR209","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/gutjnl-2019-319200","volume":"69","author":"C Heichler","year":"2020","unstructured":"Heichler C, Scheibe K, Schmied A, Geppert CI, Schmid B, Wirtz S, et al. STAT3 activation through IL-6\/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut. 2020;69(7):1269\u201382.","journal-title":"Gut"},{"issue":"3","key":"5205_CR210","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1365-2362.2010.02405.x","volume":"41","author":"CP Hsu","year":"2011","unstructured":"Hsu CP, Chen YL, Huang CC, Chou CC, Liu CL, Hung CH, et al. Anti-interleukin\u20106 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest. 2011;41(3):277\u201384.","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"5205_CR211","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.3892\/ol.2016.5227","volume":"12","author":"J Han","year":"2016","unstructured":"Han J, Xi Q, Meng Q, Liu J, Zhang Y, Han Y, et al. Interleukin-6 promotes tumor progression in colitis\u2013associated colorectal cancer through HIF-1\u03b1 regulation. Oncol Lett. 2016;12(6):4665\u201370.","journal-title":"Oncol Lett"},{"issue":"4","key":"5205_CR212","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.21037\/jgo-22-507","volume":"13","author":"J Jiang","year":"2022","unstructured":"Jiang J, Zhu F, Zhang H, Sun T, Fu F, Chen X, et al. Luteolin suppresses the growth of colon cancer cells by inhibiting the IL-6\/STAT3 signaling pathway. J Gastrointest Oncol. 2022;13(4):1722.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"5205_CR213","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3892\/ijo.2015.2851","volume":"46","author":"J Ying","year":"2015","unstructured":"Ying J, Tsujii M, Kondo J, Hayashi Y, Kato M, Akasaka T, et al. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells. Int J Oncol. 2015;46(4):1551\u20139.","journal-title":"Int J Oncol"},{"issue":"16","key":"5205_CR214","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1042\/CS20191211","volume":"134","author":"G van Duijneveldt","year":"2020","unstructured":"van Duijneveldt G, Griffin MD, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci. 2020;134(16):2091\u2013115.","journal-title":"Clin Sci"},{"issue":"6","key":"5205_CR215","doi-asserted-by":"publisher","first-page":"e20190450","DOI":"10.1084\/jem.20190450","volume":"218","author":"JE Rupert","year":"2021","unstructured":"Rupert JE, Narasimhan A, Jengelley DH, Jiang Y, Liu J, Au E, et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J Exp Med. 2021;218(6):e20190450.","journal-title":"J Exp Med"},{"issue":"4","key":"5205_CR216","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/jcla.20395","volume":"24","author":"B Mroczko","year":"2010","unstructured":"Mroczko B, Groblewska M, Gryko M, K\u0119dra B, Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C\u2010reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal. 2010;24(4):256\u201361.","journal-title":"J Clin Lab Anal"},{"key":"5205_CR217","doi-asserted-by":"crossref","unstructured":"Xing H-B, Tong M-T, Wang J, Hu H, Zhai C-Y, Huang C-X et al. Suppression of IL-6 gene by shRNA augments gemcitabine chemosensitization in pancreatic adenocarcinoma cells. BioMed research international. 2018;2018.","DOI":"10.1155\/2018\/3195025"},{"key":"5205_CR218","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s00262-005-0047-0","volume":"55","author":"G Bellone","year":"2006","unstructured":"Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother. 2006;55:684\u201398.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"5205_CR219","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers6020897","volume":"6","author":"RL Carpenter","year":"2014","unstructured":"Carpenter RL, Lo H-W. STAT3 target genes relevant to human cancers. Cancers. 2014;6(2):897\u2013925.","journal-title":"Cancers"},{"issue":"7","key":"5205_CR220","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.4161\/cbt.6.7.4328","volume":"6","author":"LW Feurino","year":"2007","unstructured":"Feurino LW, Zhang Y, Bharadwaj U, Zhang R, Li F, Fisher WE, et al. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther. 2007;6(7):1096\u2013100.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"5205_CR221","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-06-3963","volume":"67","author":"U Bharadwaj","year":"2007","unstructured":"Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res. 2007;67(11):5479\u201388.","journal-title":"Cancer Res"},{"issue":"8","key":"5205_CR222","doi-asserted-by":"publisher","first-page":"e20190673","DOI":"10.1084\/jem.20190673","volume":"217","author":"JH Lin","year":"2020","unstructured":"Lin JH, Huffman AP, Wattenberg MM, Walter DM, Carpenter EL, Feldser DM, et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J Exp Med. 2020;217(8):e20190673.","journal-title":"J Exp Med"},{"issue":"10","key":"5205_CR223","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1158\/0008-5472.CAN-12-4601","volume":"73","author":"TA Mace","year":"2013","unstructured":"Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 2013;73(10):3007\u201318.","journal-title":"Cancer Res"},{"issue":"5","key":"5205_CR224","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/ijc.29445","volume":"137","author":"FA Goumas","year":"2015","unstructured":"Goumas FA, Holmer R, Egberts JH, Gontarewicz A, Heneweer C, Geisen U, et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int J Cancer. 2015;137(5):1035\u201346.","journal-title":"Int J Cancer"},{"issue":"5","key":"5205_CR225","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.18632\/oncotarget.3099","volume":"6","author":"H Zhang","year":"2015","unstructured":"Zhang H, Wu H, Guan J, Wang L, Ren X, Shi X, et al. Paracrine SDF-1\u03b1 signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells. Oncotarget. 2015;6(5):3085.","journal-title":"Oncotarget"},{"issue":"20","key":"5205_CR226","doi-asserted-by":"publisher","first-page":"6359","DOI":"10.1158\/0008-5472.CAN-13-1558-T","volume":"73","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013;73(20):6359\u201374.","journal-title":"Cancer Res"},{"issue":"2","key":"5205_CR227","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","volume":"67","author":"TA Mace","year":"2018","unstructured":"Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67(2):320\u201332.","journal-title":"Gut"},{"key":"5205_CR228","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10637-018-0650-5","volume":"37","author":"K Ng","year":"2019","unstructured":"Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, Koh B, et al. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1\/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Investig New Drugs. 2019;37:159\u201365.","journal-title":"Investig New Drugs"},{"key":"5205_CR229","doi-asserted-by":"crossref","unstructured":"Bekaii-Saab TS, Starodub A, El-Rayes BF, Shahda S, O\u2019Neil BH, Noonan AM, et al. Phase 1b\/2 trial of cancer stemness inhibitor napabucasin (NAPA)\u2009+\u2009nab-paclitaxel (nPTX) and gemcitabine (gem) in metastatic pancreatic adenocarcinoma (mPDAC). American Society of Clinical Oncology; 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.4110"},{"issue":"12","key":"5205_CR230","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2217\/fon-2018-0903","volume":"15","author":"MB Sonbol","year":"2019","unstructured":"Sonbol MB, Ahn DH, Goldstein D, Okusaka T, Tabernero J, Macarulla T, et al. CanStem111P trial: a phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncol. 2019;15(12):1295\u2013302.","journal-title":"Future Oncol"},{"issue":"34","key":"5205_CR231","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1200\/JCO.2015.61.4578","volume":"33","author":"HI Hurwitz","year":"2015","unstructured":"Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM III, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015;33(34):4039.","journal-title":"J Clin Oncol"},{"key":"5205_CR232","doi-asserted-by":"crossref","unstructured":"Bekaii-Saab T, Okusaka T, Goldstein D, Oh D-Y, Ueno M, Ioka T et al. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. EClinicalMedicine. 2023;58.","DOI":"10.1016\/j.eclinm.2023.101897"},{"key":"5205_CR233","doi-asserted-by":"crossref","unstructured":"Akce M, Shaib WL, Diab M, Alese OB, Wu C, Thomas S, et al. Phase Ib\/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer. American Society of Clinical Oncology; 2022.","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS626"},{"key":"5205_CR234","doi-asserted-by":"crossref","unstructured":"Chen IM, Johansen JS, Theile S, Madsen K, Dajani O, Lorentzen T, et al. Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO). American Society of Clinical Oncology; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.4147"},{"issue":"2","key":"5205_CR235","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ijc.2910510220","volume":"51","author":"D Schmitter","year":"1992","unstructured":"Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer. 1992;51(2):296\u2013301.","journal-title":"Int J Cancer"},{"issue":"8","key":"5205_CR236","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1002\/1097-0142(19921015)70:8<2105::AID-CNCR2820700816>3.0.CO;2-R","volume":"70","author":"M Higashihara","year":"1992","unstructured":"Higashihara M, Sunaga S, Tange T, Oohashi H, Kurokawa K. Increased secretion of lnterleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis. Cancer. 1992;70(8):2105\u20138.","journal-title":"Cancer"},{"issue":"6","key":"5205_CR237","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/bjc.1998.150","volume":"77","author":"T Nakano","year":"1998","unstructured":"Nakano T, Chahinian A, Shinjo M, Tonomura A, Miyake M, Togawa N, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer. 1998;77(6):907\u201312.","journal-title":"Br J Cancer"},{"issue":"16","key":"5205_CR238","first-page":"4419","volume":"54","author":"G Monti","year":"1994","unstructured":"Monti G, Jaurand M-C, Monnet I, Chretien P, Saint-Etienne L, Zeng L, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by \u03b3-interferon treatment. Cancer Res. 1994;54(16):4419\u201323.","journal-title":"Cancer Res"},{"key":"5205_CR239","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF01519898","volume":"40","author":"H Bielefeldt-Ohmann","year":"1995","unstructured":"Bielefeldt-Ohmann H, Marzo A, Himbeck R, Jarnicki A, Robinson B, Fitzpatrick D. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon \u03b1 immunotherapy. Cancer Immunol Immunother. 1995;40:241\u201350.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"5205_CR240","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/ijc.22006","volume":"119","author":"Y Adachi","year":"2006","unstructured":"Adachi Y, Aoki C, Yoshio-Hoshino N, Takayama K, Curiel DT, Nishimoto N. Interleukin\u20106 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer. 2006;119(6):1303\u201311.","journal-title":"Int J Cancer"},{"key":"5205_CR241","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s002800051026","volume":"45","author":"BR McLaren","year":"2000","unstructured":"McLaren BR, Robinson BW, Lake RA. New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production. Cancer Chemother Pharmacol. 2000;45:502\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"5205_CR242","first-page":"1947","volume":"30","author":"Y Adachi","year":"2010","unstructured":"Adachi Y, Yoshio-Hoshino N, Aoki C, Nishimoto N. VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery. Anticancer Res. 2010;30(6):1947\u201352.","journal-title":"Anticancer Res"},{"issue":"1","key":"5205_CR243","first-page":"55","volume":"4","author":"SNA Rahim","year":"2015","unstructured":"Rahim SNA, Ho GY, Coward JI. The role of interleukin-6 in malignant mesothelioma. Translational lung cancer Res. 2015;4(1):55.","journal-title":"Translational lung cancer Res"},{"key":"5205_CR244","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1245\/s10434-013-2933-6","volume":"20","author":"V Vlaeminck-Guillem","year":"2013","unstructured":"Vlaeminck-Guillem V, Bienvenu J, Isaac S, Grangier B, Golfier F, Passot G, et al. Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal malignancies). Ann Surg Oncol. 2013;20:2655\u201362.","journal-title":"Ann Surg Oncol"},{"key":"5205_CR245","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1245\/s10434-015-4965-6","volume":"23","author":"S Judge","year":"2016","unstructured":"Judge S, Thomas P, Govindarajan V, Sharma P, Loggie B. Malignant peritoneal mesothelioma: characterization of the inflammatory response in the tumor microenvironment. Ann Surg Oncol. 2016;23:1496\u2013500.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"5205_CR246","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/his.13324","volume":"71","author":"NJ Carr","year":"2017","unstructured":"Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71(6):847\u201358.","journal-title":"Histopathology"},{"issue":"4","key":"5205_CR247","first-page":"445","volume":"20","author":"DH Mahe\u010di\u0107","year":"2020","unstructured":"Mahe\u010di\u0107 DH, Berkovi\u0107 MC, Zja\u010di\u0107-Rotkvi\u0107 V, \u010ca\u010dev T, Kapitanovi\u0107 S, Ulamec M. Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms. Bosnian J Basic Med Sci. 2020;20(4):445.","journal-title":"Bosnian J Basic Med Sci"},{"key":"5205_CR248","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1245\/s10434-013-3261-6","volume":"21","author":"K Lohani","year":"2014","unstructured":"Lohani K, Shetty S, Sharma P, Govindarajan V, Thomas P, Loggie B. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment. Ann Surg Oncol. 2014;21:1441\u20137.","journal-title":"Ann Surg Oncol"},{"key":"5205_CR249","doi-asserted-by":"crossref","unstructured":"Yao X, Ajani JA, Song S. Molecular biology and immunology of gastric cancer peritoneal metastasis. Translational Gastroenterol Hepatol. 2020;5.","DOI":"10.21037\/tgh.2020.02.08"},{"key":"5205_CR250","unstructured":"Posey T, Posey TA. LGR5 Regulation of STAT3 Signaling and Drug Resistance in Colorectal Cancer. 2021."},{"key":"5205_CR251","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2019.05.017","volume":"458","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Xu J, Zhang N, Chen M, Wang H, Zhu D. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Lett. 2019;458:123\u201335.","journal-title":"Cancer Lett"},{"issue":"16","key":"5205_CR252","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"R-C Investigators","year":"2021","unstructured":"Investigators R-C. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491\u2013502.","journal-title":"N Engl J Med"},{"key":"5205_CR253","doi-asserted-by":"crossref","unstructured":"Cunningham ET, Ad\u00e1n A, Nguyen QD, Zierhut M. Tocilizumab for the treatment of ocular inflammatory disease. Taylor & Francis; 2021. pp. 2\u20135.","DOI":"10.1080\/09273948.2020.1859257"},{"issue":"9","key":"5205_CR254","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TW Huizinga","year":"2014","unstructured":"Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73(9):1626\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5205_CR255","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","volume":"9","author":"F Lescure","year":"2021","unstructured":"Lescure F, Honda H, Fowler R, Lazar J, Shi G, Wung P, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):522\u201332. Copyright\u00a9 2021 Massachusetts Medical Society.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"5205_CR256","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40265-017-0724-2","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ. Sarilumab: first global approval. Drugs. 2017;77(6):705\u201312.","journal-title":"Drugs"},{"key":"5205_CR257","doi-asserted-by":"crossref","unstructured":"D\u00f6rner T, Weinblatt M, Van Beneden K, Dombrecht E, De Beuf K, Schoen P, et al. FRI0239 results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. BMJ Publishing Group Ltd; 2017.","DOI":"10.1136\/annrheumdis-2017-eular.3746"},{"issue":"22","key":"5205_CR258","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324.","journal-title":"N Engl J Med"},{"issue":"45","key":"5205_CR259","doi-asserted-by":"publisher","first-page":"26943","DOI":"10.1074\/jbc.M115.682138","volume":"290","author":"M Lacroix","year":"2015","unstructured":"Lacroix M, Rousseau F, Guilhot F, Malinge P, Magistrelli G, Herren S, et al. Novel insights into interleukin 6 (IL-6) cis-and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. J Biol Chem. 2015;290(45):26943\u201353.","journal-title":"J Biol Chem"},{"issue":"12","key":"5205_CR260","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1136\/ard-2022-222630","volume":"81","author":"E Feist","year":"2022","unstructured":"Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(12):1661\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"10289","key":"5205_CR261","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FM, Engelmann MD, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060\u20139.","journal-title":"Lancet"},{"issue":"12","key":"5205_CR262","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2217\/fon-2020-1098","volume":"17","author":"P Garrido","year":"2021","unstructured":"Garrido P, Pujol J-L, Kim ES, Lee JM, Tsuboi M, Gomez-Rueda A, et al. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. Future Oncol. 2021;17(12):1459\u201372.","journal-title":"Future Oncol"},{"key":"5205_CR263","doi-asserted-by":"crossref","unstructured":"Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Research. 2019;8.","DOI":"10.12688\/f1000research.18688.1"},{"issue":"12","key":"5205_CR264","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1002\/art.10623","volume":"46","author":"E Choy","year":"2002","unstructured":"Choy E, Isenberg D, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti\u2013interleukin\u20106 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double\u2010blind, placebo\u2010controlled, dose\u2010escalation trial. Arthr Rhuem. 2002;46(12):3143\u201350.","journal-title":"Arthr Rhuem"},{"issue":"5","key":"5205_CR265","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00063030-200317050-00006","volume":"17","author":"PROFILE AR","year":"2003","unstructured":"PROFILE AR. Anti-IL-6 receptor antibody\u2013Chugai, anti-interleukin-6 receptor antibody\u2013Chugai. MRA\u2013Chugai BioDrugs. 2003;17(5):369\u201372.","journal-title":"MRA\u2013Chugai BioDrugs"},{"issue":"4","key":"5205_CR266","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","volume":"126","author":"H Ito","year":"2004","unstructured":"Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn\u2019s disease. Gastroenterology. 2004;126(4):989\u201396.","journal-title":"Gastroenterology"},{"issue":"2","key":"5205_CR267","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3324\/haematol.2016.145060","volume":"102","author":"R Burger","year":"2017","unstructured":"Burger R, G\u00fcnther A, Klausz K, Staudinger M, Peipp M, Penas EMM, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017;102(2):381.","journal-title":"Haematologica"},{"issue":"10\u201312","key":"5205_CR268","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00011-021-01507-5","volume":"70","author":"NV Lomakin","year":"2021","unstructured":"Lomakin NV, Bakirov BA, Protsenko DN, Mazurov VI, Musaev GH, Moiseeva OM, et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflamm Res. 2021;70(10\u201312):1233\u201346.","journal-title":"Inflamm Res"},{"issue":"7","key":"5205_CR269","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, H\u00f6per H, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160(7):2354\u201366. e11.","journal-title":"Gastroenterology"},{"issue":"9","key":"5205_CR270","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jama.2023.1084","volume":"329","author":"S Zhang","year":"2023","unstructured":"Zhang S, Chen B, Wang B, Chen H, Li Y, Cao Q, et al. Effect of induction therapy with Olamkicept vs Placebo on clinical response in patients with active Ulcerative Colitis: a Randomized Clinical Trial. JAMA. 2023;329(9):725\u201334.","journal-title":"JAMA"},{"issue":"3","key":"5205_CR271","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1681\/ASN.2020071106","volume":"32","author":"K Doberer","year":"2021","unstructured":"Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, et al. A randomized clinical trial of anti\u2013IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrology: JASN. 2021;32(3):708.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"2","key":"5205_CR272","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/TP.0000000000004285","volume":"107","author":"A Borski","year":"2023","unstructured":"Borski A, Eskandary F, Haindl S, Doberer K, M\u00fchlbacher J, Mayer KA, et al. Anti-interleukin-6 antibody clazakizumab in antibody-mediated renal allograft rejection: Accumulation of antibody-neutralized Interleukin-6 without signs of Proinflammatory Rebound Phenomena. Transplantation. 2023;107(2):495\u2013503.","journal-title":"Transplantation"},{"issue":"2","key":"5205_CR273","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/bjh.15588","volume":"184","author":"DE Morra","year":"2019","unstructured":"Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, et al. Predictors of response to anti-IL 6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Br J Haematol. 2019;184(2):232\u201341.","journal-title":"Br J Haematol"},{"issue":"12","key":"5205_CR274","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1136\/annrheumdis-2017-211328","volume":"76","author":"T Takeuchi","year":"2017","unstructured":"Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R, et al. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017;76(12):2001\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5205_CR275","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1365-2125.2011.03964.x","volume":"72","author":"Z Xu","year":"2011","unstructured":"Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti\u2010IL\u20106 monoclonal antibody (sirukumab) in healthy subjects in a first\u2010in\u2010human study. Br J Clin Pharmacol. 2011;72(2):270\u201381.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"5205_CR276","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14712598.2022.2078160","volume":"22","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, Prajapati R, Lathigara D, Nagar B, Kukadiya J, Redwan EM, et al. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther. 2022;22(6):763\u201380.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"5205_CR277","doi-asserted-by":"publisher","first-page":"e28900","DOI":"10.1002\/pbc.28900","volume":"68","author":"P Merli","year":"2021","unstructured":"Merli P, Quintarelli C, Strocchio L, Locatelli F. The role of interferon-gamma and its signaling pathway in pediatric hematological disorders. Pediatr Blood Cancer. 2021;68(4):e28900.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05205-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05205-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05205-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:27:15Z","timestamp":1714498035000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05205-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":277,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5205"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05205-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"402"}}